Epigenetic alterations are a hallmark of cancer that govern the silencing of genes. Up to now, 5-azacytidine (5-aza-CR, Vidaza™) and 5-aza-2'-deoxycytidine (5-aza-dC, Dacogen™) are the only clinically approved DNA methyltransferase inhibitors (DNMTi). Current effort tries to exploit DNMTi application beyond acute leukemia or myelodysplastic syndrome, especially to solid tumors. Although both drugs only differ by a minimal structural difference, they trigger distinct molecular mechanisms that are highly relevant for a rational choice of new combination therapies. Therefore we investigated cell death pathways in vitro in human hepatoma, colon, renal and lung cancer cells and in vivo in chorioallantoic membrane and xenograft models. Real-time cancer cell monitoring and cytokine profiling revealed a profoundly distinct response pattern to both drugs. 5-aza-dC induced p53-dependent tumor cell senescence and a high number of DNA double strand breaks. In contrast, 5-aza-CR downregulated p53, induced caspase activation and apoptosis. These individual response patterns of tumor cells could be verified in vivo in chorioallantoic membrane assays and in a hepatoma xenograft model. Although 5-aza-CR and 5-aza-dC are viewed as drugs with similar therapeutical activity, they induce a diverse molecular response in tumor cells. These findings together with other reported differences enable and facilitate a rational design of new combination strategies to further exploit the epigenetic mode of action of these two drugs in different areas of clinical oncology.
Introduction
The two DNA methyltransferase inhibitors (DNMTi) 5-azacytidine (5-aza-CR, Vidaza™) and 5-aza-2'-deoxycytidine (5-aza-dC, decitabine, Dacogen™) are clinically approved for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Whereas both drugs are able to induce complete responses and hematological improvements, a prolonged overall survival could only be shown for 5-aza-CR, but not for 5-aza-dC (1, 2) .
However, at the moment there is no specific guideline that governs which of these two substances should be preferred in a specific clinical context. The development of novel dosing strategies or the combination with other antitumor therapies hold promise to exploit the activities of DNMTi compounds for an improved therapeutic effect either in hematological malignancies or even in hitherto unaddressed tumor entities, such as solid tumors. In accordance with this rationale, several clinical studies currently investigate the application of 5-aza-CR or 5-aza-dC in combination with other anticancer strategies, including chemotherapeutic or targeted agents. For a purposeful combination of DNMTi substances with other anticancer principles it is of utmost importance to exactly define the individual tumor cell response pattern to each distinct DNMTi compound.
Although both DNMTi only minimally differ in their molecular structure, there are important differences in their molecular mode of action (3, 4) .
As a general principle, successful antitumor strategies have to efficiently trigger death pathways. In recent years, therapy-induced senescence (TIS) has become an important issue in the field of tumor biology and cancer therapy. It is well known that senescence as a permanent growth arrest can be induced by a variety of stimuli, ranging from oxidative stress, DNA damage, oncogenic stress, telomere shortening or epigenetic alterations (5) (6) (7) . However, the concept of TIS as a new mechanism of anticancer agents emerged by the observation that some well-known drugs can potently trigger tumor cell senescence (8) (9) (10) . Thus, a therapeutically induced permanent growth arrest seems to be an attractive new option that might be suitable for a broad range of tumor entities (7) . However, it is currently not clear whether the success of such a concept requires a second step that subsequently eliminates the resulting senescent cancer cells.
5-aza-dC has been reported to induce senescence by upregulation of p16(INK4a) in oral squamous cell carcinoma and heptocellular carcinoma (HCC) cell lines (11, 12) . In contrast, comparable results for 5-aza-CR are missing. As compounds with TIS activity should ideally not be used in combination with antitumor approaches that require cell division, such as 
Real-time cell analysis
HepG2 cells (1 x 10 4 cells/well) or Hep3B cells (2.5 x 10 3 cells/well) were seeded in 96-well
plates (E-Plate 96, Roche Applied Science, Mannheim, Germany). Real-time dynamic cell proliferation was monitored in 30 min intervals for more than 106 h using the xCELLigence RTCA SP system (Roche Applied Science) and cell index values were calculated using the RTCA Software (1.0.0.0805). All curves were normalized at the beginning of the treatment period, 10 h after seeding, applying the RTCA Software. Hypodiploid (sub2N) cells were considered apoptotic.
Measurement of the cellular diameter
HepG2 cells (7.5 x 10 4 cells/well) were cultured on cover slips for 24 h in 24-well plates.
Each cover slip was transferred to a separate cell culture chamber of a PANsys 3000 system (PAN-Systech GmbH, Aidenbach, Germany) and treated with 20 µM 5-aza-CR or 5-aza-dC.
The identical observation point in each chamber was monitored for a total time span of 96 h by phase-contrast microscopy. The maximum diameter of 20 representative cells in each cell 
H3K9me3-staining
To detect histone H3 lysine-9 trimethylation (H3K9me3) HepG2 cells ( antibodies.
Densitometric analysis
X-ray films of Western blots and cytokine profiling arrays were digitized with an imaging system (FluoChem TM 8900, Alpha Innotech, San Leandro, USA). Densitometric analyses were performed using ImageJ (version 1.6.0_14). In brief, bands were surrounded by rectangle and plotted. The background was subtracted from the obtained peak and the area under the peak was calculated. 
Histology and immunohistochemistry
Tumor specimens were removed from the xenografted mice, fixed in formalin and embedded in paraffin. Serial sections were routinely stained with hematoxylin and eosin. After Medical Systems, Tucson, AZ, USA). The histologic analysis was performed by a pathologist in a blinded fashion.
Chorioallantoic membrane assay
The chorioallantoic membrane (CAM) assay was done as described (13) . Briefly, 1 x 10 6 HepG2 cells were implanted on fertilized chicken eggs on day 8 of incubation and treated with vehicle (control) or 5-10 µM 5-aza-CR and 5-aza-dC, respectively. After 3 days, tumors were sampled with the surrounding CAM, fixed in 4% paraformaldehyde, embedded in paraffin, cut in 5 µm sections and stained with hematoxylin and eosin. The histologic analysis was performed by a pathologist in a blinded fashion.
Statistical analysis
Statistical analyses were performed either with an unpaired Student's t test or a MannWhitney test using GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA, USA).
According to this analysis, the following three different P values were examined: a P value of 0.01 to 0.05 (*), a P value of 0.001 to 0.01 (**) and a P value < 0.001 (***). 
Results

Differential effects of 5-aza-CR and 5-aza-dC on cellular morphology
To investigate the cellular reaction patterns to 5-aza-CR and 5-aza-dC, we first employed real-time measurements of the cellular impedance using the xCELLigence SP system (14, 15) over a 96 h time period. The cellular impedance is depicted by the cell index (CI) and a reduction of the CI indicates reduced viability or induction of apoptosis, whereas increased CI values indicate proliferation or increased cell size (6, 15, 16) . Unexpectedly, we observed differential effects of 5-aza-CR and 5-aza-dC treatment on HepG2 and Hep3B hepatoma cells for all tested concentrations (Fig. 1A) . Incubation of both cell lines with 5-aza-CR at concentrations from 5 µM to 50 µM led to a reduction of the normalized CI in comparison to untreated cells. In contrast, 5-aza-dC treatment increased the normalized CI of HepG2 cells.
In additionally performed experiments a CI increase was even found for 1 µM and 0.5 µM of 5-aza-dC (data not shown). Interestingly, this 5-aza-dC-mediated effect was not detectable in Hep3B cells. The most prominent difference between these two hepatoma cell lines is their different p53 status: HepG2 are p53 wild-type expressing cells, whereas Hep3B cells are p53-deficient (17) .
To further characterize the differential results of the real-time cell monitoring for 5-aza-CR and 5-aza-dC, a sulforhodamine B cytotoxicity assay was performed (Fig. 1B) . Incubation of 
cell size, a significant increase in the cellular diameter was observed when HepG2 cells were incubated with 5-aza-dC for 72 h or 96 h (Supplementary Table S1 ; **P < 0.01, ***P < 0.001). These results comply with the findings of the real-time cell monitoring and indicate that the 5-aza-dC-mediated increase of the CI in the p53 wild-type cell line HepG2 was based on an increment of the cell size, which is a known hallmark of cellular senescence.
5-aza-dC but not 5-aza-CR induces cellular senescence
To further investigate a potential senescence induction by the DNMTi 5-aza-dC, the expression of the senescence-associated marker β-galactosidase (SA-β-gal) was determined.
HepG2 and Hep3B cells were treated for 72 h with 20 µM 5-aza-CR or 5-aza-dC. This time point was chosen due to the divergent curve progression in the real-time monitoring and the results of the cellular size measurement. Incubation with 5-aza-dC, but not 5-aza-CR, led to a significant increase (***P < 0.001) in the number of SA-β-gal-positive HepG2 cells ( Fig. 2A) displaying a characteristic blue staining (Fig. 2B) .
Another marker for senescence is the accumulation of trimethylated histone H3 lysine-9 (H3K9me3), which is involved in the formation of so-called senescence-associated heterochromatin foci (SAHF) (18, 19) . We therefore investigated SAHF formation by immunofluorescence microscopy of H3K9me3 in HepG2 cells (Fig. 2C) 
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has at least in some models not been a reliable marker for cellular senescence. Thus, other classic senescence markers, such as the cell cycle inhibitor p16(INK4a) have been suggested to be applied instead (9) . In our model we therefore investigated on the one hand p16 ( (Fig. 2E and Supplementary Fig. S1 ). Interestingly, all three molecules have previously been associated with cellular senescence (22, 23, 24, 25) . In contrast to 5-azadC, 5-aza-CR led to a reduced secretion of sICAM-1 and IL-1ra, which might be a result of protein synthesis inhibition by this compound. IL-8, however, was upregulated by both DNMTi (Fig. 2E) . Interestingly, increased IL-8 expression has been described as a molecular marker for hepatotoxicity in HepG2 cells (26) other cell types (27, 28) . Hence, induction of IL-8 expression by 5-aza-CR could rather be explained as a sign of cytotoxicity than as an effect of cellular senescence. Of note, both drugs did not induce an increase of IL-8 in p53-deficient Hep3B cells.
DNMTi 5-aza-CR directly activates cell death instead of cellular senescence
5-aza-CR possesses a ribonucleoside structure and can be incorporated into both RNA and DNA, whereas 5-aza-dC, based on its deoxyribonucleoside structure, can be inserted into DNA only (3, 29, 30) . Due to this different chemical structure 5-aza-CR appears to be more toxic and a less potent DNMTi at comparable concentrations. To determine whether 5-aza-CR induces other cellular pathways than senescence, apoptosis was analyzed by flow cytometric measurement of cells with hypodiploid DNA (Fig. 3A and B) . Incubation with 5-aza-CR resulted in a dose-dependent increase of hypodiploid HepG2 and Hep3B cells after 48 h and 72 h, whereas 5-aza-dC showed only a marginal alteration in HepG2 cells. Due to the prodrug characteristics of 5-aza-CR and to exclude a too low dosage of 5-aza-CR in comparison to 5-aza-dC also a concentration of 100 µM was tested by FACS analysis at these two time points.
Again, 5-aza-CR displayed a pronounced increase in the sub2N fraction under this dosage ( Supplementary Fig. S2A and B) . In addition, caspase-3/7-activity (being used as an indicator for apoptosis) was assessed after 5-aza-CR or 5-aza-dC treatment, including the 100 µM concentration ( Supplementary Fig. S2C and D) . necrosis by 5-aza-CR treatment, whereas 5-aza-dC had no relevant effect (Fig. 3C) . Thus, 5-aza-CR is able to induce caspase activation, cell death and substantial tumor necrosis in vivo.
Notably, this observation is in clear contrast to the senescent phenotype induced by 5-aza-dC.
5-aza-dC induces profound DNA damage, while 5-aza-CR reduces cellular p53 levels
Several DNA damage pathways can induce cellular senescence. We therefore analyzed the occurrence of double-strand breaks upon 5-aza-CR or 5-aza-dC treatment by measuring the phosphorylation of H2A.X in HepG2 cells (Fig. 4A) . In line with published data (3), we detected a significant increase of phosphorylated γH2A.X by 5-aza-dC in a similar concentration range that induced senescence. 5-aza-CR, in contrast, only caused marginal DNA-damaging effects ( Fig. 4A ; **P < 0.01, ***P < 0.001).
Unlike 5-aza-dC, 5-aza-CR is known to block RNA synthesis (3, 30) , followed by inhibition of protein synthesis, which might especially affect short-lived proteins, such as p53 (3, 4) . For this reason, the protein levels of p53 in HepG2 cells were determined by Western blotting after 5-aza-CR or 5-aza-dC treatment (Fig. 4B) . Notably, p53 levels showed a dose-dependent decline, which started to occur already within 24 h of treatment with 5-aza-CR but not 5-azadC (Fig. 4B) . Of note, as described in the literature, no expression of p53 was detectable in Hep3B hepatoma cells (Supplementary Fig. S3 ). In addition, alterations of p53 levels were investigated in other p53 wild-type harboring tumor cells, including HCT-116 colon, A498 kidney and A549 lung carcinoma cells. Remarkably, in all tumor cell lines, a dose-dependent decline in p53 protein levels was detected upon 5-aza-CR treatment ( Fig. 5A and Supplementary Fig. S4A and C) . In contrast, 5-aza-dC rather led to an increase in p53 protein levels, which might be related to the senescence-inducing capacity of this drug. In line with p53 wild-type HepG2 cells, treatment with 20 µM 5-aza-dC induced a significant increase of SA-β-gal staining in these solid tumor cells (Fig. 5B and Supplementary Fig. S4B and D) . 
Discussion
Both, 5-aza-CR and 5-aza-dC were originally developed as nucleoside antimetabolites for anti-cancer therapy (30, 31) . Both drugs are analogues of cytidine and share the same basic chemical structure with only small differences in the ribose backbone. For this reason 5-aza-CR and 5-aza-dC are supposed to exhibit a similar mode of action by inhibiting cellular DNA methyltransferases (31). Both azanucleosides have been shown to be effective in the treatment of MDS and AML and are currently the only FDA-approved DNMTi compounds (3). In some tumor models, such as oral squamous cell carcinoma or HCC, 5-aza-dC induces cancer cell senescence (11, 12) . This has led to the hypothesis that either DNA hypomethylation or an alteration of the DNA structure might be involved in senescence induction (8, 32) . Therefore, it might be reasoned that compounds with DNMTi activity generally induce tumor cell senescence by DNA demethylation. However, according to our in vitro and in vivo experiments, only 5-aza-dC induced a senescent phenotype in p53 wild-type tumor cells. In contrast, a dose-dependent reduction of viability, induction of cell death and decline of p53 protein levels were observed upon 5-aza-CR treatment in different tumor cell lines. These results further imply important differences of these two closely related and clinically applied demethylating compounds in solid tumor cells. Concerning AML as a disease in which both substances are currently in clinical use, a recent publication reported e.g. that only about 30% of tumor cells with a complex karyotype are p53 wild-type (33). To our knowledge, it is not known so far, whether p53 wild-type AML patients differentially respond to 5-aza-CR and 5-aza-dC. As a starting point from our manuscript it would be interesting to directly compare these response patterns in different AML populations which could possibly lead to the identification of patient subgroups that benefit most from either 5-aza-CR or 5-aza-dC. 
its ribonucleoside analogue 5-aza-CR (3, 34) . Furthermore, even at similar concentrations 5-aza-CR and 5-aza-dC induce quite different changes in gene expression patterns, as e.g.
shown in several comparative gene array analyses, mainly in AML cells (34) (35) (36) . In light of these data, it is not surprising that both substances differ in their mode of action, including the induction of senescence in p53 wild-type solid tumor cells exclusively by 5-aza-dC.
Noteworthy, an elegant recent study that investigated the transient application of 5-aza-CR and 5-aza-dC reported that already low doses exerted distinct alterations in several signaling pathways in leukemia cell lines and primary cancer cells, respectively (37) .
Another contribution to TIS induction might be the higher amount of DNA strand breaks that are triggered by 5-aza-dC compared to 5-aza-CR (38) . It is well known that DNA damage signaling pathways are designated activators of cellular senescence (7) effects of both compounds on antiproliferative activity, cytotoxicity, gene demethylation, transcription, NK cell activity or DNA repair (34, 36, (41) (42) (43) (44) (45) (46) (47) (48) (49) . A comprehensive overview of these differences is summarized in Table 1 . Thus, although 5-aza-CR and 5-aza-dC are often viewed as mechanistically similar, our results clearly emphasize specific differences between both drugs, which have to be considered for the further development of these compounds, especially in combination approaches with other anticancer strategies. The diameter of 20 cells/group was measured in a randomized fashion and calculated as mean ± SD; Mann-Whitney test, **P < 0.01, ***P < 0.001; ns: not significant. 
